All In MedTech

Device Trial Radar · NCT05486481

Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)

A Multicenter Phase 1/2 Study of Venetoclax/Daratumumab/Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis With Translocation (11;14)

Last checked: Nov 20, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Jan 8, 2024

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Alfred Chung, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Janssen Pharmaceuticals; AbbVie
First posted
Aug 3, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial tests the safety, side effects, and best dose of venetoclax, daratumumab, and dexamethasone for the treatment of systemic light-chain amyloidosis in patients with a deoxyribonucleic acid (DNA) abnormality called a translocation involving chromosomes 11 and 14, or "t(11;14)". Venetoclax works by attaching to a protein called Bcl-2, in order to kill cancer cells. Daratumumab works by binding to a target on the surface of cancer cells called Cluster of differentiation 38 (CD38). When daratumumab binds to CD38, it enables the immune system to find the cancer cell and kill it. Dexamethasone is a type of drug called a corticosteroid. A corticosteroid is a drug made of artificial steroid hormones, that are used to treat symptoms such as inflammation (swelling and irritation to a part of the body). The combination of these medications may more effectively treat patients with systemic light-chain amyloidosis and t(11;14).

Conditions

  • AL Amyloidosis
  • Light Chain (AL) Amyloidosis
  • Systemic Light Chain Disease

Interventions

  • VenetoclaxDrug

    Given orally (PO)

  • DexamethasoneDrug

    Given PO

  • DaratumumabDrug

    Given Subcutaneously (SC)

  • Cyclin D1 gene (CCDN1) /immunoglobulin heavy chain (IGH) fluorescence in situ hybridization (FISH) assayDevice

    Lab test

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with reported dose limiting toxicities (Phase 1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)
  2. Maximum tolerated dose (MTD) (Phase 1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)
  3. Recommended phase 2 dose (RP2D) (Phase1)Time frame: Up to 1 cycle (1 cycle is equal to 28 days)

1 more outcomes with a free account

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.